Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30875941 | 0.84 | DRD2 (0.39) | DRD2CACNA1HALDH1A1GFERTHRB | |
| SCHEMBL513795 | 0.83 | MEN1 (0.55) | DRD2CACNA1HALDH1A1GFERSIGMAR1 | |
| SCHEMBL31301221 | 0.82 | DRD2 (0.55) | DRD2CACNA1HALDH1A1GFERSIGMAR1 | |
| SCHEMBL21389284 | 0.81 | DRD2 (0.52) | DRD2CACNA1HALDH1A1GFERSIGMAR1 | |
| SCHEMBL18850988 | 0.80 | SMN1; SMN2 (0.43) | THRBMEN1KMT2A | |
| SCHEMBL26452488 | 0.80 | KMT2A (0.53) | DRD2CACNA1HALDH1A1GFERMEN1 | |
| SCHEMBL165469 | 0.79 | SMN1; SMN2 (0.44) | THRBMEN1KMT2A | |
| SCHEMBL22783648 | 0.78 | DRD2 (0.52) | DRD2CACNA1HALDH1A1GFERSIGMAR1 | |
| SCHEMBL31301242 | 0.78 | DRD2 (0.63) | DRD2CACNA1HALDH1A1GFERSIGMAR1 | |
| SCHEMBL30923338 | 0.77 | SMN1; SMN2 (0.43) | ALDH1A1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608454-A1 | SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION | Eli Lilly and Company (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024092219-A1 | SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION | ELI LILLY AND COMPANY (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-110475777-B | Novel pyrido [2,3-b ] indole compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2018-11-01 | — | — | US | disclosed |
| WO-2017075694-A1 | ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR | SIMON FRASER UNIVERSITY (CA) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017075694-A1 | ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR | SIMON FRASER UNIVERSITY (CA) | 2017-05-11 | — | — | WO | disclosed |
| US-7759340-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20090181955-A1 | Antibacterial Agents | MILLER WILLIAM HENRY | 2009-07-16 | — | — | US | disclosed |
| US-7511035-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-03-31 | — | — | US | disclosed |
| US-20080139539-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | DRD2 914/4885CACNA1H 1290/4885ALDH1A1 3305/4885 |
| US-20080139539-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | DRD2 2082/4885CACNA1H 4397/4885ALDH1A1 2845/4885 |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | DRD2 180/4885CACNA1H 2754/4885ALDH1A1 1539/4885 |
| US-20090181955-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | DRD2 2082/4885CACNA1H 4397/4885ALDH1A1 2845/4885 |
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | UGT1A8, CYP2C8, CXCL8 | DRD2 4251/4885CACNA1H 4003/4885ALDH1A1 803/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | DRD2 1019/4885CACNA1H 1473/4885ALDH1A1 3367/4885 |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | HCK, BTK, LYN | DRD2 4597/4885CACNA1H 4652/4885ALDH1A1 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.